Ipsen showcases studies at the ESMO 2019 Congress highlighting progress in new approaches for difficult-to-treat cancers
Presentations demonstrate promising advances for the treatment of advanced hepatocellular carcinoma, metastatic pancreatic cancer and neuroendocrine tumors
Paris (France), 26 September 2019 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that clinical trials with cabozantinib (Cabometyx®) in a variety of tumor types will be the subject of four presentations at the European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona, Spain, from 27 September – 1 October 2019.
“At Ipsen, our mission is to accelerate the discovery, development and commercialization of new medicines. So, we’re delighted to be sharing new studies at ESMO that demonstrate potential advances in treatment for select cancers where few effective therapeutic options exist, so no patient is left behind,” said Dr. Alexandre Lebeaut, Ipsen’s Executive Vice President, R&D and Chief Scientific Officer.
Key studies including Ipsen medicines to be presented at ESMO 2019 Congress:
- An overview of the trial design of the pivotal Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma (aHCC) who have not received prior systemic anticancer therapy
- A new QTWiST analysis of the Phase III CELESTIAL study looking at the effect of second-line cabozantinib on health states for patients with aHCC after sorafenib
“While we’re making strides in our own research programs for other hard-to-treat-cancers, like small cell lung cancer and pancreatic adenocarcinoma, our complementary work with partners is catalyzing and broadening our efforts to fast-track new approaches for patients with significant unmet needs,” said Bartek Bednarz, Ipsen, Senior Vice-President, Oncology Franchise. “ESMO 2019 marks an important milestone for our partnership with Exelixis to further develop cabozantinib (Cabometyx®), as we have exceeded 100 joint cabozantinib-related abstracts accepted to medical congresses in our shared vision to progress the treatment for difficult-to-treat cancers.”
Follow Ipsen on Twitter via @IpsenGroup and keep up to date with ESMO 2019 Congress news and updates by using the hashtag #ESMO19.
Overview of key presentations featuring Ipsen medicines in development at the ESMO 2019 Congress:
| Medicine | Abstract title | Abstract number/timing (CEST) |
| Cabometyx® (cabozantinib)
|
Effect of second-line cabozantinib on health states for patients with advanced hepatocellular carcinoma (aHCC) after sorafenib: QTWiST analysis from the CELESTIAL study | Abstract 754P – Poster Display – Sunday, 29 September, 12:00 PM; Hall 4 |
| Outcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC) | Abstract 678PD – Poster Discussion – Category: Gastrointestinal tumours, non-colorectal – Saturday, 28 September, 5:10 PM; Hall 7 | |
| Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC) | Abstract 749P – Poster Display – Sunday, 29 September, 12:00 PM; Hall 4 | |
| Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab vs sorafenib in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received prior systemic anticancer therapy | Abstract 833TiP – Poster Display – Sunday, 29 September, 12:00 PM; Hall 4 | |
| Onivyde® (irinotecan liposome injection) (nal-IRI/liposomal irinotecan) | Integrated population pharmacokinetic modelling of liposomal irinotecan in patients with various tumour types, including untreated metastatic pancreatic cancer (mPC) | Abstract 691P – Poster Display – Sunday, 29 September, 12:00 PM; Hall 4 |
| Somatuline® Autogel® (lanreotide autogel/depot) | Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120 mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen | Abstract 1388P – Poster Display – Sunday, 29 September, 12:00 PM; Hall 4 |
Key investigator sponsored study presentation featuring Ipsen medicine in development at the ESMO 2019 Congress:
| Medicine | Abstract title | Abstract number/timing (CEST) |
| Onivyde® (irinotecan liposome injection) (nal-IRI/liposomal irinotecan) | Multicenter randomized phase II trial of 5-Fluorouracil/leucovorin (5-FU/LV) with or without liposomal irinotecan (nal-IRI) in metastatic biliary tract cancer (BTC) as second-line therapy after progression on gemcitabine plus cisplatin (GemCis): NIFTY trial |
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases
Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform
Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer
Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis